LUN Stock Overview
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally.
H. Lundbeck Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.172.70|
|52 Week High||kr.207.30|
|52 Week Low||kr.142.60|
|1 Month Change||8.28%|
|3 Month Change||7.94%|
|1 Year Change||-10.77%|
|3 Year Change||-31.98%|
|5 Year Change||-52.65%|
|Change since IPO||246.96%|
Recent News & Updates
|LUN||DK Pharmaceuticals||DK Market|
Return vs Industry: LUN underperformed the Danish Pharmaceuticals industry which returned 6.9% over the past year.
Return vs Market: LUN underperformed the Danish Market which returned -2.8% over the past year.
|LUN Average Weekly Movement||5.0%|
|Pharmaceuticals Industry Average Movement||5.6%|
|Market Average Movement||6.4%|
|10% most volatile stocks in DK Market||10.9%|
|10% least volatile stocks in DK Market||3.5%|
Stable Share Price: LUN is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: LUN's weekly volatility (5%) has been stable over the past year.
About the Company
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company’s principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer’s disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington’s disease, as well as other products.
H. Lundbeck Fundamentals Summary
|LUN fundamental statistics|
Is LUN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LUN income statement (TTM)|
|Cost of Revenue||kr.3.51b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 17, 2022
|Earnings per share (EPS)||5.58|
|Net Profit Margin||6.76%|
How did LUN perform over the long term?See historical performance and comparison
Is LUN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LUN?
Other financial metrics that can be useful for relative valuation.
|What is LUN's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does LUN's PE Ratio compare to its peers?
|LUN PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
ALK B ALK-Abelló
NOVO B Novo Nordisk
ORNBV Orion Oyj
LUN H. Lundbeck
Price-To-Earnings vs Peers: Insufficient data to calculate LUN's Price-To-Earnings Ratio vs. peers for valuation analysis.
Price to Earnings Ratio vs Industry
How does LUN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: Insufficient data to calculate LUN's Price-To-Earnings Ratio vs. industry for valuation analysis.
Price to Earnings Ratio vs Fair Ratio
What is LUN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||n/a|
|Fair PE Ratio||29.7x|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LUN's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of LUN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: LUN (DKK172.7) is trading below our estimate of fair value (DKK558.6)
Significantly Below Fair Value: LUN is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LUN's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is H. Lundbeck forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LUN's forecast earnings growth (26.1% per year) is above the savings rate (0.09%).
Earnings vs Market: LUN's earnings (26.1% per year) are forecast to grow faster than the Danish market (9.4% per year).
High Growth Earnings: LUN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: LUN's revenue (6.3% per year) is forecast to grow slower than the Danish market (6.4% per year).
High Growth Revenue: LUN's revenue (6.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LUN's Return on Equity is forecast to be low in 3 years time (15.5%).
Discover growth companies
How has H. Lundbeck performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LUN has a large one-off loss of DKK702.0M impacting its March 31 2022 financial results.
Growing Profit Margin: LUN's current net profit margins (6.8%) are lower than last year (12.1%).
Past Earnings Growth Analysis
Earnings Trend: LUN's earnings have declined by 13.9% per year over the past 5 years.
Accelerating Growth: LUN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LUN had negative earnings growth (-47.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.9%).
Return on Equity
High ROE: LUN's Return on Equity (6%) is considered low.
Discover strong past performing companies
How is H. Lundbeck's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: LUN's short term assets (DKK9.0B) exceed its short term liabilities (DKK7.8B).
Long Term Liabilities: LUN's short term assets (DKK9.0B) exceed its long term liabilities (DKK8.8B).
Debt to Equity History and Analysis
Debt Level: LUN's net debt to equity ratio (23.5%) is considered satisfactory.
Reducing Debt: LUN's debt to equity ratio has increased from 18% to 32.2% over the past 5 years.
Debt Coverage: LUN's debt is well covered by operating cash flow (33%).
Interest Coverage: LUN's interest payments on its debt are well covered by EBIT (17.2x coverage).
Discover healthy companies
What is H. Lundbeck current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LUN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LUN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LUN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LUN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LUN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Deborah Dunsire (59 yo)
Dr. Deborah Dunsire, M.D. serves as Director at Syros Pharmaceuticals, Inc. since September 09, 2021. She serves as Chief Executive Officer and President at H. Lundbeck A/S since September 1, 2018 and serv...
CEO Compensation Analysis
Compensation vs Market: Deborah's total compensation ($USD8.01M) is above average for companies of similar size in the Danish market ($USD3.23M).
Compensation vs Earnings: Deborah's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: LUN's management team is considered experienced (3.3 years average tenure).
Experienced Board: LUN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
H. Lundbeck A/S's employee growth, exchange listings and data sources
- Name: H. Lundbeck A/S
- Ticker: LUN
- Exchange: CPSE
- Founded: 1915
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr.34.306b
- Shares outstanding: 198.65m
- Website: https://www.lundbeck.com
Number of Employees
- H. Lundbeck A/S
- Ottiliavej 9
- Capital Region of Denmark
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/10 00:00|
|End of Day Share Price||2022/06/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.